GB2456390A - Bipolar disorder treatments - Google Patents

Bipolar disorder treatments Download PDF

Info

Publication number
GB2456390A
GB2456390A GB0800702A GB0800702A GB2456390A GB 2456390 A GB2456390 A GB 2456390A GB 0800702 A GB0800702 A GB 0800702A GB 0800702 A GB0800702 A GB 0800702A GB 2456390 A GB2456390 A GB 2456390A
Authority
GB
United Kingdom
Prior art keywords
bipolar disorder
test compound
screening
disorder treatments
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB0800702A
Other versions
GB0800702D0 (en
Inventor
Pierandrea Muglia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GB0800702A priority Critical patent/GB2456390A/en
Publication of GB0800702D0 publication Critical patent/GB0800702D0/en
Publication of GB2456390A publication Critical patent/GB2456390A/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/304—Mood disorders, e.g. bipolar, depression

Abstract

A method of screening a small molecule compound for use in treating bipolar disorder comprises screening a test compound against a target selected from the group consisting of the gene products encoded by the genes listed in Table 3 and/or Table 4, wherein activity against said target indicates the test compound has potential use in treating bipolar disorder. The genes were identified by identifying polymorphisms which show correlation with bipolar disorder, such as the rs9651273 polymorphism on the C1orf159 gene.
GB0800702A 2008-01-15 2008-01-15 Bipolar disorder treatments Pending GB2456390A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0800702A GB2456390A (en) 2008-01-15 2008-01-15 Bipolar disorder treatments

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0800702A GB2456390A (en) 2008-01-15 2008-01-15 Bipolar disorder treatments

Publications (2)

Publication Number Publication Date
GB0800702D0 GB0800702D0 (en) 2008-02-20
GB2456390A true GB2456390A (en) 2009-07-22

Family

ID=39144965

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0800702A Pending GB2456390A (en) 2008-01-15 2008-01-15 Bipolar disorder treatments

Country Status (1)

Country Link
GB (1) GB2456390A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8680239B2 (en) 2000-12-22 2014-03-25 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Use of RGM and its modulators
US8906864B2 (en) 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US9102722B2 (en) 2012-01-27 2015-08-11 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
US9175075B2 (en) 2009-12-08 2015-11-03 AbbVie Deutschland GmbH & Co. KG Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein
US10414755B2 (en) 2017-08-23 2019-09-17 Novartis Ag 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US11185537B2 (en) 2018-07-10 2021-11-30 Novartis Ag 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US11192877B2 (en) 2018-07-10 2021-12-07 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP2023506637A (en) * 2020-01-22 2023-02-17 清華大学 Use of Synaptotagmin-7 in Diagnosis and Treatment of Bipolar Disorder

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110172507A (en) * 2019-06-11 2019-08-27 中国人民解放军第四军医大学 A kind of Large Vestibular Aqueduct/Pendred syndrome Disease-causing gene SLC26A4 abrupt climatic change kit
CN110272992B (en) * 2019-06-27 2023-06-27 郑湘榕 Kit and reagent for detecting childhood asthma based on GLCCI1 gene rs37972 locus and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066672A2 (en) * 2001-01-16 2002-08-29 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists
WO2006081350A2 (en) * 2005-01-26 2006-08-03 Rutgers, The State University Of New Jersey Methods and compositions for the diagnosis and treatment of schizophrenia
WO2008036437A2 (en) * 2006-04-19 2008-03-27 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066672A2 (en) * 2001-01-16 2002-08-29 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists
WO2006081350A2 (en) * 2005-01-26 2006-08-03 Rutgers, The State University Of New Jersey Methods and compositions for the diagnosis and treatment of schizophrenia
WO2008036437A2 (en) * 2006-04-19 2008-03-27 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Molecular Psychiatry (2008); Vol 13, pp 197-207, "A genome-wide association study implicates...", Baum et al *
NCBI Accession No CAI14316 (2004); "Chromosome 1 open reading frame 159 [Homo sapiens], Matthews *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8680239B2 (en) 2000-12-22 2014-03-25 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Use of RGM and its modulators
US8906864B2 (en) 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US9605069B2 (en) 2008-02-29 2017-03-28 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM a protein and uses thereof
US9175075B2 (en) 2009-12-08 2015-11-03 AbbVie Deutschland GmbH & Co. KG Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein
US9102722B2 (en) 2012-01-27 2015-08-11 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
US9365643B2 (en) 2012-01-27 2016-06-14 AbbVie Deutschland GmbH & Co. KG Antibodies that bind to repulsive guidance molecule A (RGMA)
US10106602B2 (en) 2012-01-27 2018-10-23 AbbVie Deutschland GmbH & Co. KG Isolated monoclonal anti-repulsive guidance molecule A antibodies and uses thereof
US10414755B2 (en) 2017-08-23 2019-09-17 Novartis Ag 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US10640489B2 (en) 2017-08-23 2020-05-05 Novartis Ag 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US10647701B2 (en) 2017-08-23 2020-05-12 Novartis Ag 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US11053218B2 (en) 2017-08-23 2021-07-06 Novartis Ag 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US11185537B2 (en) 2018-07-10 2021-11-30 Novartis Ag 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US11192877B2 (en) 2018-07-10 2021-12-07 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US11833142B2 (en) 2018-07-10 2023-12-05 Novartis Ag 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP2023506637A (en) * 2020-01-22 2023-02-17 清華大学 Use of Synaptotagmin-7 in Diagnosis and Treatment of Bipolar Disorder

Also Published As

Publication number Publication date
GB0800702D0 (en) 2008-02-20

Similar Documents

Publication Publication Date Title
GB2456390A (en) Bipolar disorder treatments
TN2011000221A1 (en) Pyrazine compounds as phosphodiesterase 10 inhibitors
WO2010045318A3 (en) Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
PH12021550686A1 (en) Compositions and methods for lactate dehydrogenase (ldha) gene editing
WO2008097277A3 (en) Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181
NZ590750A (en) Methods and compositions for improving the production of products in microorganisms, especially clostridium phytofermentans
TN2010000096A1 (en) Oxadiazole - and oxazole - substituted benzimidazole - and indole - derivatives as dgat1 inhibitors
JO2872B1 (en) New Compounds
TN2011000220A1 (en) Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
MX2009004047A (en) Organic compounds.
EP3467123A3 (en) Methods and compositions of molecular profiling for disease diagnostics
WO2008094545A3 (en) Mic orna-based methods and compositions for the treatment of acute myeloid leukemia
MX2007009809A (en) Selection probe amplification.
WO2010034838A3 (en) Antiproliferative compounds
WO2008079374A3 (en) Methods and compositions for selecting and using single nucleotide polymorphisms
WO2017201102A8 (en) Method of improved sequencing by strand identification
BR112012009144B8 (en) rostafuroxin, method for identifying an individual with the best response to rostafuroxin and kit of parts to evaluate the treatment of rostafuroxin for an individual
WO2008112659A3 (en) Regulation of osteopontin
MX2008011175A (en) Phosphodiesterase 10 inhibitors.
WO2007100777A3 (en) Methods for the treatment of adhd and related disorders
MX340807B (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system.
WO2009120712A3 (en) Compositions and methods for diagnosing and treating melanoma
TW200806297A (en) Methods for treating cognitive and other disorders
MY184632A (en) A method of identifying parentage in freshwater prawn macrobrachium rosenbergii
MX2009004382A (en) Genetic variations associated with tumors.